Page 42 - TD-4-1

Tumor Discovery CDK4/6 inhibitor resistance in breast cancer

2. Dar H, Johansson A, Nordenskjold A, et al. Assessment of 2023;25(1):103.
25-year survival of women with estrogen receptor-positive/ doi: 10.1186/s13058-023-01701-9
ERBB2-negative breast cancer treated with and without
tamoxifen therapy: A secondary analysis of data from the 11. Goetz MP, Toi M, Huober J, et al. Abemaciclib plus a
stockholm tamoxifen randomized clinical trial. JAMA Netw nonsteroidal aromatase inhibitor as initial therapy for HR+,
Open. 2021;4(6):e2114904. HER2- advanced breast cancer: final overall survival results
of MONARCH 3. Ann Oncol. 2024;35(8):718-727.
doi: 10.1001/jamanetworkopen.2021.14904
doi: 10.1016/j.annonc.2024.04.013
3. Chua AV Jr., Sheng H, Liang E, et al. Epidemiology of early
vs late recurrence among women with early stage estrogen 12. Xu XQ, Pan XH, Wang TT, et al. Intrinsic and acquired
receptor-positive breast cancer in the Pathways Study. J Natl resistance to CDK4/6 inhibitors and potential overcoming
Cancer Inst. 2024;116(10):1621-31. strategies. Acta Pharmacol Sin. 2021;42(2):171-178.
doi: 10.1093/jnci/djae128 doi: 10.1038/s41401-020-0416-4
4. Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent 13. Xue Y, Zhai J. Strategy of combining CDK4/6 inhibitors with
progress of CDK4/6 inhibitors’ current practice in breast other therapies and mechanisms of resistance. Int J Clin Exp
cancer. Cancer Gene Ther. 2024;31(9):1283-1291. Pathol. 2024;17(7):189-207.
doi: 10.1038/s41417-024-00747-x doi: 10.62347/HGNI4903
5. Knudsen ES, Witkiewicz AK. The strange case of CDK4/6 14. Du Q, Guo X, Wang M, Li Y, Sun X, Li Q. The application
inhibitors: Mechanisms, resistance, and combination and prospect of CDK4/6 inhibitors in malignant solid
strategies. Trends Cancer. 2017;3(1):39-55. tumors. J Hematol Oncol. 2020;13(1):41.
doi: 10.1016/j.trecan.2016.11.006 doi: 10.1186/s13045-020-00880-8
6. Rastogi P, O’Shaughnessy J, Martin M, et al. Adjuvant 15. Watt AC, Goel S. Cellular mechanisms underlying response
abemaciclib plus endocrine therapy for hormone receptor- and resistance to CDK4/6 inhibitors in the treatment of
positive, human epidermal growth factor receptor 2-negative, hormone receptor-positive breast cancer. Breast Cancer Res.
high-risk early breast cancer: Results from a preplanned 2022;24(1):17.
monarchE overall survival interim analysis, including 5-year
efficacy outcomes. J Clin Oncol. 2024;42(9):987-993. doi: 10.1186/s13058-022-01510-6
16. George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S.
doi: 10.1200/JCO.23.01994
Clinical and pharmacologic differences of CDK4/6 inhibitors
7. Hortobagyi GN, Lacko A, Sohn J, et al. A phase III trial of in breast cancer. Front Oncol. 2021;11:693104.
adjuvant ribociclib plus endocrine therapy versus endocrine
therapy alone in patients with HR-positive/HER2-negative doi: 10.3389/fonc.2021.693104
early breast cancer: final invasive disease-free survival results 17. Pandey K, An HJ, Kim SK, et al. Molecular mechanisms of
from the NATALEE trial. Ann Oncol. 2024;36(2):149-157. resistance to CDK4/6 inhibitors in breast cancer: A review.
Int J Cancer. 2019;145(5):1179-1188.
doi: 10.1016/j.annonc.2024.10.015
doi: 10.1002/ijc.32020
8. Li H, Wu Y, Zou H, et al. Clinical efficacy of CDK4/6 inhibitor
plus endocrine therapy in HR-positive/HER2-0 and HER2- 18. Chen X, Shen K. Dalpiciclib in advanced breast cancer.
low-positive metastatic breast cancer: A secondary analysis Lancet Oncol. 2023;24(6):578-579.
of PALOMA-2 and PALOMA-3 trials. EBioMedicine. doi: 10.1016/S1470-2045(23)00228-0
2024;105:105186.
19. Huang J, Zheng L, Sun Z, Li J. CDK4/6 inhibitor resistance
doi: 10.1016/j.ebiom.2024.105186
mechanisms and treatment strategies (Review). Int J Mol
9. Lu YS, Im SA, Colleoni M, et al. Updated overall survival Med. 2022;50(4):128.
of ribociclib plus endocrine therapy versus endocrine
therapy alone in pre- and perimenopausal patients with doi: 10.3892/ijmm.2022.5184
HR+/HER2- advanced breast cancer in MONALEESA-7: 20. Chang CM, Lam HYP. Mechanism of CDK4/6 inhibitor
A phase III randomized clinical trial. Clin Cancer Res. resistance in hormone receptor-positive breast cancer
2022;28(5):851-859. and alternative treatment strategies. Anticancer Res.
2023;43(12):5283-5298.
doi: 10.1158/1078-0432.CCR-21-3032
doi: 10.21873/anticanres.16732
10. Neven P, Fasching PA, Chia S, et al. Updated overall
survival from the MONALEESA-3 trial in postmenopausal 21. Zhou FH, Downton T, Freelander A, Hurwitz J, Caldon CE,
women with HR+/HER2- advanced breast cancer receiving Lim E. CDK4/6 inhibitor resistance in estrogen receptor
first-line ribociclib plus fulvestrant. Breast Cancer Res. positive breast cancer, a 2023 perspective. Front Cell Dev

Volume 4 Issue 1 (2025) 34 doi: 10.36922/td.7107